227 related articles for article (PubMed ID: 9692651)
1. The pharmacology and therapeutic utility of bisphosphonates.
Lourwood DL
Pharmacotherapy; 1998; 18(4):779-89. PubMed ID: 9692651
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials with bisphosphonates.
Lombardi A; Santora AC
Ann Ital Med Int; 1992; 7(3 Suppl):158S-165S. PubMed ID: 1297394
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates in the treatment of disorders of mineral metabolism.
Singer FR; Minoofar PN
Adv Endocrinol Metab; 1995; 6():259-88. PubMed ID: 7671099
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of action of the bisphosphonates.
Fleisch H
Medicina (B Aires); 1997; 57 Suppl 1():65-75. PubMed ID: 9567358
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.
Fleisch H
Drugs; 1991 Dec; 42(6):919-44. PubMed ID: 1724640
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition.
Drake MT; Cremers SC
Mol Interv; 2010 Jun; 10(3):141-52. PubMed ID: 20539033
[TBL] [Abstract][Full Text] [Related]
7. [Development of bisphosphonates].
Nakatsuka K
Nihon Rinsho; 2003 Feb; 61(2):219-25. PubMed ID: 12638211
[TBL] [Abstract][Full Text] [Related]
8. The use of bisphosphonates in osteoporosis.
Fleisch H
Br J Clin Pract; 1994; 48(6):323-6. PubMed ID: 7848797
[TBL] [Abstract][Full Text] [Related]
9. [Bisphosphonates in the treatment of multiple myeloma].
Stajszczyk M
Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates: expanded roles in the treatment of patients with cancer.
Viale PH; Sanchez Yamamoto D
Clin J Oncol Nurs; 2003; 7(4):393-401. PubMed ID: 12929272
[TBL] [Abstract][Full Text] [Related]
11. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates and osteonecrosis: potential treatment or serious complication?
Goytia RN; Salama A; Khanuja HS
Orthop Clin North Am; 2009 Apr; 40(2):223-34. PubMed ID: 19358907
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological therapy of Paget's and other metabolic bone diseases.
Hosking D
Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
[TBL] [Abstract][Full Text] [Related]
14. [Bisphosphonates: pharmacology and use in the treatment of osteoporosis].
Kishimoto H
Nihon Rinsho; 1998 Jun; 56(6):1531-6. PubMed ID: 9648477
[TBL] [Abstract][Full Text] [Related]
15. Management of Paget's disease of bone.
Langston AL; Ralston SH
Rheumatology (Oxford); 2004 Aug; 43(8):955-9. PubMed ID: 15187244
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
Li B; Ling Chau JF; Wang X; Leong WF
J Cell Biochem; 2011 May; 112(5):1229-42. PubMed ID: 21465521
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates: mode of action and pharmacology.
Russell RG
Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid (Zometa) use in bone disease.
Theriault RL
Expert Rev Anticancer Ther; 2003 Apr; 3(2):157-66. PubMed ID: 12722875
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
Grewal VS; Fayans EP
Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
[TBL] [Abstract][Full Text] [Related]
20. [Preclinical toxicology of bisphosphonates].
Mondelo N; Peluffo VA; Parma MD; Cointry GR; Capozza RF; Ferretti JL; Piccinni E; Montuori E
Medicina (B Aires); 1997; 57 Suppl 1():93-100. PubMed ID: 9567361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
